Mirati (Lung Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to see how a combination of an experimental drug, MRTX849, and an approved drug (pembrolizumab) work in your body and against your cancer.

What is the Condition Being Studied?

Advanced Lung Cancer (Non-Small Cell Lung Cancer)

Who Can Participate in the Study?

Adults age 18 or older who:
- Are diagnosed with advanced non-small cell lung cancer which has tested positive for the KRAS tumor gene

For more information about who can be in this study, please contact the study team.

Age Group
Adults

What is Involved?

This study has 2 parts: a screening period and a study dosing period.

If you join this study, during the screening period you will:
- Have a sample of your tumor tested for the KRAS tumor gene
- Have blood draws
- Visit the clinic for various tests to see if you’re eligible for the dosing period

If you're eligible for the dosing period, you will:
- Have blood draws
- Have imaging scans (CT and MRI)
- Receive study drugs
-- MRTX849 is taken by mouth twice each day.
-- Pembrolizumab is given by injection into a vein every 3 weeks.

You will continue taking study drugs as long as you are benefitting for up to a maximum of 24 months.

Study Details

Full Title
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation. 849-007. KRYSTAL 7.
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00107219
NCT: NCT04613596
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698